Liver disease has been identified as a leading cause of death in HIV-infected patients since the introduction of highly active antiretroviral therapy (HAART) in 1996. The HIV treatment community has been caught largely unaware of this emerging dilemma. Many HIV care providers are ill-equipped to understand and interpret liver injury patterns, or to provide comprehensive care and management for viral coinfections which they are not familiar with. HIV and Liver Disease provides a comprehensive update of the field covering the epidemiology, pathogenesis, management and treatment of liver disease in patients with HIV infection. The volume will help HIV care providers understand and interpret liver injury patterns, and/or provide comprehensive care and management for viral coinfections. Gastroenterologists and hepatologists will gain an understanding of complex drug regimens that are used to treat HIV and which may impact HCV and HBV treatment. Written by expert clinicians and researchers across multiple disciplines, HIV and Liver Disease will be of great value to gastroenterologists, hepatologists, infectious disease practitioners, as well as other health care providers who provide care or participate in research in the field of HIV.

Infectious diseases are the leading cause of death globally, particularly among children and young adults. The spread of new pathogens and the threat of antimicrobial resistance pose particular challenges in combating these diseases. Major Infectious Diseases identifies feasible, cost-effective packages of interventions and strategies across delivery platforms to prevent and treat HIV/AIDS, other sexually transmitted infections, tuberculosis, malaria, adult febrile illness, viral hepatitis, and neglected tropical diseases. The volume emphasizes the need to effectively address emerging antimicrobial resistance, strengthen health systems, and increase access to care. The attainable goals are to reduce incidence, develop innovative approaches, and optimize existing tools in resource-constrained settings.

Authoritative new text from the experts in GI populationstudies This book covers both key methodological issues and the mostimportant information in the field, disease by disease. It focuseson population-based information and studies looking at principlesand approaches to diagnosis and treatment of diseases. GI Epidemiology brings together world authorities inmultiple disciplines for the very first time, to create one clearand comprehensive source. The bulk of the chapters are divided intotwo parts, covering methodological issues and the epidemiology ofspecific GI diseases. Each chapter begins with a list of keypoints, followed by a review written in a clear and simplestyle. The methodologic chapters cover evidence-based medicine,meta-analysis, systematic reviews, genetic and molecularepidemiology, clinical trials, questionnaire design, and healtheconomics. The disease-specific chapters note the current gaps inknowledge and suggest areas for further study. GI Epidemiology serves as both a useful refresher and areliable reference on the methods and techniques used inepidemiological studies for consultants and researchers ingastroenterology. It is also an invaluable tool for fellows/trainees ingastroenterology, candidates for recertification in the combineddisciplines of gastroenterology, pediatric gastroenterology andcolorectal surgery, and anyone completing MPH training.

The Social Security Administration (SSA) uses a screening tool called the Listing of Impairments to identify claimants who are so severely impaired that they cannot work at all and thus qualify for disability benefits. In this report, the Institute of Medicine (IOM) makes several recommendations for improving SSA's capacity for determining disability benefits more accurately and quickly using the HIV Infection Listings.

Drug-Induced Liver Injury, Volume 85, the newest volume in the Advances in Pharmacology series, presents a variety of chapters from the best authors in the field. Chapters in this new release include Cell death mechanisms in DILI, Mitochondria in DILI, Primary hepatocytes and their cultures for the testing of drug-induced liver injury, MetaHeps an alternate approach to identify IDILI, Autophagy and DILI, Biomarkers and DILI, Regeneration and DILI, Drug-induced liver injury in obesity and nonalcoholic fatty liver disease, Mechanisms of Idiosyncratic Drug-Induced Liver Injury, the Evaluation and Treatment of Acetaminophen Toxicity, and much more. - Includes the authority and expertise of leading contributors in pharmacology - Presents the latest release in the Advances in Pharmacology series

Here's instant access to the symptoms, signs, differential diagnosis, and treatment for the full range of liver disorders. Written by an international 'who's who' of hepatology-and now in full color-this new 2nd Edition provides readers with top-notch, authoritative guidance they can count on! Discusses the hottest topics in the field, such as non-alcoholic steatohepatitis (NASH) and the latest information on liver transplantation. Includes expanded coverage of chronic hepatitis C, most notably the use of combination therapy with peginterferon and ribavirin and improvements in the management of the side effects of antiviral therapy. Offers the most recent therapeutic options for the management of chronic hepatitis B and advances in the understanding of the molecular biology of this virus. Updates the approach to the diagnosis of many liver diseases due to newer tests based on molecular techniques and advances in imaging. Features over 340 full-color illustrations. Uses a redesigned templated, outline format that makes reference a snap. Presents a concise, in-depth clinical summary-in an outline format-of the current practice of hepatology for each major disease entity. Provides a liberal use of tables, algorithms, and figures, rendering complex concepts understandable. Includes key point boxes at the beginning of each chapter, providing at-a-glance access to vital information. Includes alert symbols that highlight information that's critical to patient safety.

The Pocket Book is for use by doctors nurses and other health workers who are responsible for the care of young children at the first level referral hospitals. This second edition is based on evidence from several WHO updated and published clinical guidelines. It is for use in both inpatient and outpatient care in small hospitals with basic laboratory facilities and essential medicines. In some settings these guidelines can be used in any facilities where sick children are admitted for inpatient care. The Pocket Book is one of a series of documents and tools that support the Integrated Managem.

Hepatitis B and C cause most cases of hepatitis in the United States and the world. The two diseases account for about a million deaths a year and 78 percent of world's hepatocellular carcinoma and more than half of all fatal cirrhosis. In 2013 viral hepatitis, of which hepatitis B virus (HBV) and hepatitis C virus (HCV) are the most common types, surpassed HIV and AIDS to become the seventh leading cause of death worldwide. The world now has the tools to prevent hepatitis B and cure hepatitis C. Perfect vaccination could eradicate HBV, but it would take two generations at least. In the meantime, there is no cure for the millions of people already infected. Conversely, there is no vaccine for HCV, but new direct-acting antivirals can cure 95 percent of chronic infections, though these drugs are unlikely to reach all chronically-infected people anytime soon. This report, the first of two, examines the feasibility of hepatitis B and C elimination in the United States and identifies critical success factors. The phase two report will outline a strategy for meeting the elimination goals discussed in this report.

Completely revised new edition of the premier reference on pediatric liver disease. Liver Disease in Children, 3rd Edition provides authoritative coverage of every aspect of liver disease affecting infants, children, and adolescents. The book offers an integrated approach to the science and clinical practice of pediatric hepatology and charts the substantial progress in understanding and treating these diseases. Chapters are written by international experts and address the unique pathophysiology, manifestations, and management of these disorders in the pediatric population. The third edition has been thoroughly updated and features new contributions on liver development, cholestatic and autoimmune disorders, fatty liver disease, and inborn errors of metabolism. With the continued evolution of pediatric hepatology as a discipline, this text remains an essential reference for all physicians involved in the care of children with liver disease.

One of the most important aspects of AIDS is the loss of protective immune function in the infected host which leads to increased prevalence of opportunistic infections and cancers. This book specifically addresses viral-induced human cancers associated with AIDS and observed in the AIDS population. It addresses the specific treatment required in this special population and the molecular biology of the causative viral agents.